Nabriva Therapeutics plc (NBRVF)

OTCMKTS · Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
At close: Mar 3, 2026
100.00%
Market Cap 646.00
Revenue (ttm) 29.56M
Net Income (ttm) -55.05M
Shares Out 3.23M
EPS (ttm) -17.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 756
Average Volume 1,437
Open 0.0002
Previous Close n/a
Day's Range 0.0002 - 0.0002
52-Week Range n/a
Beta -0.84
RSI 57.47
Earnings Date n/a

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); XENLETA for the treatment of community-acquired bacterial pneumonia; and CONTEPO for the treatment of complicated urinary tract infections, including acute pyelonephritis. The company was formerly known as Nabriva Therapeutics ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 39
Stock Exchange OTCMKTS
Ticker Symbol NBRVF
Full Company Profile

Financial Performance

In 2022, Nabriva Therapeutics's revenue was $36.94 million, an increase of 27.82% compared to the previous year's $28.90 million. Losses were -$57.19 million, 15.6% more than in 2021.

Financial Statements

News

There is no news available yet.